Bizhen Lin

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Fanghui Zhao, Ting Wu, Yuemei Hu et al. · The Lancet Infectious Diseases · 2022 · 85 citations

Vaccination, Vaccine Safety, L1 Virus-like-particle Vaccine +11

Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response

Chunlan Zhuang, Zhijie Lin, Zhaofeng Bi et al. · Emerging Microbes & Infections · 2021 · 55 citations · Full text

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

Yuemei Hu, Meng Guo, Changgui Li et al. · Science China Life Sciences · 2019 · 51 citations · Full text

Vaccination, Human Papillomavirus Vaccines, Immunogenicity Noninferiority Study +7

Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study

Xingmei Yao, Wen Chen, Chao Zhao et al. · The Lancet Regional Health - Western Pacific · 2021 · 24 citations · Full text

Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages

Qi Chen, Hui Zhao, Xingmei Yao et al. · Vaccine · 2020 · 14 citations

Vaccination, Cervical Cancer, Vaccine Development +12